Huntington’s disease (HD) is a rare progressive neurological disorder characterized by movement disorders, cognitive decline, behavioral changes, and psychiatric disturbances. Current treatment is entirely dependent on symptomatic therapies and includes a cocktail of antidepressants, antipsychotics, and antiepileptics to control patients’ cognitive, behavioral, and neurological symptoms. Treatment for chorea is limited to tetrabenazine and Teva’s Austedo (deutetrabenazine), which launched in 2017 in the United States. HD is a debilitating condition, and available treatments are only marginally effective, leaving tremendous need for effective disease-modifying therapies (DMTs). Ionis/Roche’s HTTRx/RG6042 is an antisense oligonucleotide being evaluated in Phase III trials for HD. The therapy has the potential to modify disease course and, accordingly, has garnered interest among treating physicians. Furthermore, the Phase II HD pipeline also includes a variety of additional symptom-targeting and potential disease-modifying therapies, any of which stands to capitalize on the significant commercial opportunity in HD if its efficacy is demonstrated.

Questions Answered

  • How large is the diagnosed Huntington’s population in the United States and EU5? How will the population change by 2029?
  • What is the current treatment landscape in Huntington’s disease, and how will it change in the next ten years?
  • What do key opinion leaders view as the greatest unmet medical needs in the management of Huntington’s disease?
  • What do neurologists consider the most promising emerging therapies for HD to be, and which are likely to launch by 2029?

Product Description

Niche & Rare Disease Landscape & Forecast: comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Huntington's Disease - Landscape & Forecast - Disease Landscape & Forecast

Author(s): Raina Priyadarshini, Ph.D

Raina is a senior analyst on the Infectious, Rare, and Niche Diseases team at Decision Resources Group.

Before joining DRG, Raina worked in drug development for novel disease targets. She gained experience assessing market research and competitive intelligence in rare disorders in multiple therapy areas.

She holds a Ph.D. in molecular biology from the National Institute of Immunology in India.